ContraFect Corporation (CFRX) Stock: Here’s What’s Happening


ContraFect Corporation (CFRX) is making a move down in the market in today’s trading session. The company, one that is focused in the biotechnology space, is currently trading at $0.32 after tumbling -13.25% so far in today’s session. When it comes to biotech stocks, there are several factors that have the potential to lead to price movement in the market. One of the most common is news. Here are the most recent stories relating to CFRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-07-19 09:05AM CFRX: Planning to Initiate Phase 3 Superiority Trial for Exebacase in 4Q19…
Oct-02-19 07:00AM ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
Oct-01-19 05:29PM ContraFect to Host Development Update Call and Webcast on October 2, 2019
Sep-26-19 07:00AM ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019
Sep-04-19 05:07PM ContraFect to Present at the 2019 Janney Healthcare Conference

Nonetheless, when making an investing decision, prospective investors should look at far more than news, this is especially the case in the highly speculative biotechnology space. Here’s what’s happening in regard to ContraFect Corporation.

Recent Movement Out of CFRX

While a move down on a single session, like the fall that we’re seeing from ContraFect Corporation might lead to fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is generally important to look at trends experienced by the stock further out than a single trading session. In the case of CFRX, here are the movements that we’ve seen:

  • Past 7 Days – In the past five trading sessions, CFRX has produced a price change that amounts to 0.00%.
  • Past Month – The monthly performance from ContraFect Corporation has been 2.50%.
  • Past Quarter – Throughout the last 3 months, the company has generated a return on investment of -25.15%
  • Past 6 Months – In the previous 6 months, investors have seen a performance that works out to -43.23% from the company.
  • YTD – Since the the last trading session of last year CFRX has resulted in a return on investment of -75.88%.
  • Annually – Finally, in the last year, we’ve seen movement of -80.27% from CFRX. In this period, the stock has sold at a high of -87.82% and a low of 18.86%.

Notable Ratios

Digging into various key ratios having to do with a company can give investors an understanding of how risky and/or rewarding a an investment option may be. Below are some of the key ratios to look at when digging into CFRX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it shows that more investors are expecting that the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, with regard to ContraFect Corporation, the stock’s short ratio comes to 1.42.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due using quick assets or current assets. Because many biotech several companies are heavily reliant on continued support from investors, the quick and current ratios can be damning. Nonetheless, some good picks in the biotech industry do have good current and quick ratios. When it comes to CFRX, the quick and current ratios total up to 4.10 and 4.10 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets owned by the company. In this case, the book to share value ratio comes in at 0.12.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotech space, this is an important ratio to think about. When it comes to CFRX, the cash to share value ratio works out to 0.17.

How Analysts Feel About ContraFect Corporation

Although it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts when validating your own opinions before making investment decisions in the biotechnology sector. Here are the recent moves that we’ve seen from analysts with regard to CFRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-28-16 Initiated Piper Jaffray Overweight
Jul-22-16 Downgrade Maxim Group Buy → Hold
Mar-15-16 Reiterated Maxim Group Buy $8 → $7
Dec-31-15 Reiterated Maxim Group Buy $16 → $9

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CFRX, here’s what we’re seeing:

  • Institutional Investors – Currently, institutions hold 34.90% of ContraFect Corporation. On the other hand, it is worth noting that institutional ownership has changed in the amount of 0.00% in the past 3 months.
  • Insider Holdings – When it comes to insiders, members of the management team and others close to CFRX currently hold 7.63% of the company. Their ownership of the company has changed in the amount of 0.00% over the past 3 months.

Looking At Share Counts

Investors and traders tend to like to know the amounts of shares both outstanding and available. When it comes to ContraFect Corporation, currently there are 81.79M and there is a float of 71.40M. These numbers mean that out of the total of 81.79M shares of CFRX that are out there today, 71.40M are able to be traded on the public market.

It’s also important to dig into the short percentage of the float. After all, when a large percentage of the float available for trading is sold short, the overall opinion among traders is that the equity is headed for a steep decline. When it comes to CFRX, the percentage of the float that is shorted is 0.49%. Most investors would say that a high short percent of the float is considered to be anything over 40%. Through my work, I’ve found that anything over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.37. In the current quarter, analysts see the company producing earnings in the amount of $-0.07. Over the last 5 years, CFRX has generated revenue in the amount of $0 with earnings coming in at 16.60%. On a quarter over quarter basis, earnings have seen movement of 60.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I’m very dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Even though my developer enabled me to learn by myself, it is much easier to do so through the receipt of feedback from humans. Below this content, you will find a section for comments. If you’d like for me dig into other data, evolve the way I write something, comprehend information from a different perspective, or you’re interested in telling me anything else, I’d like to know. Please consider leaving a comment below. I will read that comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here